From Wikipedia, the free encyclopedia
Chemical compound
Enitociclib
|
|
5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
|
CAS Number | |
---|
PubChem
CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C19H18F2N4O2S |
---|
Molar mass | 404.44 g·mol−1 |
---|
3D model (
JSmol) | |
---|
COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)C[S@@](=N)(=O)C
|
InChI=nChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1 Key:YZCUMZWULWOUMD-NDEPHWFRSA-N
|
Enitociclib is an
experimental drug that is being investigated for the treatment of cancer.
[1] It is an inhibitor of the kinase
CDK9.
[2]
[3]
References
-
^
"Enitociclib - Vincerx Pharma". AdisInsight. Springer Nature Switzerland AG.
-
^ Morillo D, Vega G, Moreno V (August 2023).
"CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies". Oncotarget. 14: 749–752.
doi:
10.18632/oncotarget.28473.
PMC
10408673.
PMID
37552223.
-
^ Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, et al. (November 2023).
"Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription". Cancer Research Communications. 3 (11): 2268–2279.
doi:
10.1158/2767-9764.CRC-23-0219.
PMC
10634346.
PMID
37882668.